Sandu Pharmaceuticals Ltd — Important, 11-08-2026: Company Update

Sandu Pharmaceuticals' board approved the financial results for the quarter, reporting revenue from operations of 16.39 Cr and a profit for the period of 0.03 Cr. The board also endorsed the appointment of M/s. Dave & Dave as statutory auditors for five years, pending shareholder approval. Additionally, it put forward the continuation of material related party transactions with M/s. Sandu Brothers Private Limited for member approval. The 41st Annual General Meeting will be held virtually, with a record date set for dividend eligibility from the last financial year.